Zoladex (gozerelin) capsules for subcutaneous use 3.6 mg.


Prostate cancer: therapy for prostate cancer, which may have a hormonal effect; endometriosis; uterine fibroma; with in vitro fertilization; the need for thinning of the endometrium before planned operations; breast cancer (hormone-dependent) in reproductive age and perimenopause.



Composition and form of release

Zoladex is produced in capsules with a prolonged action and intended for subcutaneous administration. The main active ingredient of the drug is goserelin acetate.


Zoladex is used to treat:

  • breast cancer;
  • prostate cancer;
  • uterine fibroids;
  • endometriosis.

In addition, the use of Zoladex is appropriate for the treatment of endometrial thinning before the planned surgical treatment of the endometrium, it is also prescribed to patients before in vitro fertilization.


Zoladex is not prescribed to lactating women, pregnant women and those with hypersensitivity to goserelin acetate.

Use during pregnancy and breastfeeding

Zoladex is not used in the treatment of pregnant women, as it has a pronounced negative effect on fetal development and significantly increases the risk of miscarriage.

Method of application and dose

Zoladex is administered subcutaneously to adults in the anterior abdominal wall every 28 days. In the treatment of malignant neoplasms it is used for a long time. In the treatment of benign gynecological diseases, the drug is not recommended for use for more than 6 months.

In the treatment of the endometrium, patients receive one injection every 4 weeks, a total of two injections. When the drug is administered, uterine ablation should be performed for the first time two weeks after the second dose is administered to the patient.

In preparation for in vitro fertilization, a woman receives Zoladex to desensitize the pituitary gland.

No dosage adjustment is required when using the drug for the treatment of elderly patients, as well as those suffering from severe hepatic or renal insufficiency.


There were no clinically significant symptoms in patients using Zoladex in high doses. If any adverse symptoms develop during Zoladex treatment, symptomatic treatment is recommended.

Side effects

During treatment with Zoladex, some patients may develop lability of blood pressure, nonspecific paresthesias, pituitary apoplexy, arthralgia, allergic reactions manifested by skin rash.

In men, the introduction of Zoladex may cause hot flashes, sweating, decreased potency, soreness and swelling of the mammary glands. Sometimes when using a drug for the treatment of prostate cancer at the beginning of therapy may cause bone pain, impaired urethral patency, compression of the spinal cord. Also in some patients, a decrease in bone density is possible.

In some women, taking Zoladex may be accompanied by the development of hot flashes, increased sweating, impaired libido, changes in the size of the mammary glands, emotional lability, dryness of the vaginal mucosa. At the beginning of therapy, breast cancer patients may experience an increase in symptoms, but this is a temporary phenomenon that passes quickly.

Sometimes taking the drug can be accompanied by the formation of corpus luteum cysts and follicular cysts, which can be of different sizes and prone to spontaneous resorption.

Conditions and terms of storage

Zoladex is stored in a dark, dry place. The shelf life of the drug is 3 years.